# CH7057288

**Cat. No.:** HY-107362

**CAS No.:** 2095616-82-1

**Molecular Formula:** $C_{32}H_{31}N_3O_5S$

**Molecular Weight:** 569.67

**Target:** Trk Receptor

**Pathway:** Neuronal Signaling; Protein Tyrosine Kinase/RTK

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 6 months |
| | -20°C | 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : ≥ 34 mg/mL (59.68 mM)

$H_2O$ : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.7554 mL | 8.7770 mL | 17.5540 mL |
| 5 mM | 0.3511 mL | 1.7554 mL | 3.5108 mL |
| 10 mM | 0.1755 mL | 0.8777 mL | 1.7554 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.75 mg/mL (4.83 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

CH7057288 is a potent and selective TRK inhibitor.

**$IC_{50}$ & Target**

TRK

**In Vitro**

CH7057288 induces regression of intracranial tumors and greatly improves event-free survival in an intracranial implantation model mimicking brain metastasis. CH7057288 can be a promising therapeutic agent for TRK fusion-positive cancer. TRK receptor tyrosine kinases are expressed as fusion proteins encoded by various fusion genes across a wide variety of cancer types, including lung and colorectal cancer[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Hiroshi Tanaka, et al. Abstract 4179: Potent and selective TRK inhibitor CH7057288. AACR Annual Meeting 2017; April 1-5, 2017.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA